Topical corticosteroids are recommended as first-line treatment for all levels of atopic dermatitis, as well as for ...

Reviewed By Steven R. Feldman, MD, PhD, Professor of Dermatology, Pathology and Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina Coping with the symptoms ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Over the past ...

Please provide your email address to receive an email when new articles are posted on . Once-daily roflumilast 0.05% cream improved atopic dermatitis in children aged 2 to 5 years compared with ...

Please provide your email address to receive an email when new articles are posted on . Safety and tolerability were similar in both treatment groups. Roflumilast showed significant improvement across ...

Experts discuss the importance of balancing effective symptom control with quality of life in managing chronic pediatric atopic dermatitis, emphasizing personalized treatment plans that address both ...

Credit: Getty Images. Clinical phenotypes of atopic dermatitis can vary greatly based on skin color and can make atopic dermatitis difficult to diagnose. Recognizing the clinical diversity of ...

Nektar Therapeutics (NASDAQ:NKTR) shares climbed 3.6% on Monday after the biotech firm unveiled encouraging new data showing ...

Once-daily, effective, safe, and well-tolerated ZORYVE cream now commercially available Provides rapid clearance of atopic dermatitis signs and symptoms and significant reduction in itch, and can be ...

SILVERBERG: As a board-certified dermatologist in an academic referral center, I encounter a substantial caseload of patients with atopic dermatitis and other chronic inflammatory skin conditions.

Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2ZORYVE cream 0.05% ...

Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) stock rose 3.6% on Monday after the company presented new data showing its experimental drug rezpegaldesleukin improved asthma symptoms in patients ...